Genomic characterization of invasive typhoidal and non-typhoidal *Salmonella* in southwestern Nigeria

Odion O. Ikhimiukor[1], Anderson O. Oaikhena[1], Ayorinde O. Afolayan[1], Abayomi Fadeyi[2], Aderemi Kehinde[3], Victoria Ogunleye[3], Aaron O. Aboderin[4], Oyinlola O. Oduyebo[5], Charles J. Elikwu[6], Erkison Ewomazino Odih[1], Ifeoluwa Komolafe[1], Silvia Argimón[7], Abiodun Egwuenu[8], Ini Adebiyi[3], Oluwadamiloa A. Sadare[6], Tochi Okwor[8], Mihir Kekre[7], Anthony Underwood[7], Chikwe Ihekweazu[8], David M. Aanensen[7] and Iruka N. Okeke[1]

[1] Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance, Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Ibadan, Oyo State, Nigeria.

[2] Department of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Kwara State, Nigeria.

[3] Department of Medical Microbiology and Parasitology, University College Hospital, Ibadan, Oyo State, Nigeria.

[4] Department of Medical Microbiology and Parasitology, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.

[5] Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria

[6] Department of Medical Microbiology, School of Basic Clinical Sciences, Benjamin Carson College of Health and Medical Sciences, Babcock University & Teaching Hospital, Ilishan-Remo, Ogun State, Nigeria.

[7] Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford, Oxford, United Kingdom.

[8] Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria.

ABSTRACT

Background: Salmonellosis causes significant morbidity and mortality in Africa. Despite

being endemic in Nigeria, information on circulating lineages of invasive *Salmonella* is

sparse.

Methods: Sixty-three *Salmonella enterica* isolated from blood (n=60) and cerebrospinal fluid

(CSF, n=3) isolated between 2016 and 2020 from five tertiary hospitals in southwest Nigeria

were Illumina-sequenced and analysed using publicly available bioinformatic tools.

Results: Isolates and sequence types (STs) from blood were *S*. Typhi [ST1 =1 and ST2 =43]

and invasive non-typhoidal *Salmonella* (iNTS) (*S*. *Enteritidis* [ST11, n=7], *S*. Durham [ST10,

n=2], *S*. Rissen [ST8756, n=2], *S*. Chester [ST2063, n=1], *S*. Dublin [ST10, n=1], *S*. Infantis

[ST603, n=1], *S*. Telelkebir [ST8757, n=1] and *S*. Typhimurium [ST313, n=1], whereas it

was *S*. Typhi ST2 (n=2) and *S*. Adabraka ST8757 (n=1) from CSF. Most *S*. Typhi belonged

to genotype 3.1.1 (n=44, 95.7%) and had several antibiotic resistance genes (ARGs)

including *bla*$_{TEM-1}$ (86.4%, n=38), *aph(6)-Id* (72.7%, n=32), *tet(A)* (75%, n=33), *sul2* (72.7%,

n=32), *dfrA14* (68.18%, n=30) as well as the quinolone resistance-conferring *gyrA_S83Y*

SNPs (n=37, 84.09%). The 3.1.1 strains included a predominant sub-lineage (n=33)

harbouring *gyrA_S83Y* and an IncY plasmid detected at all hospitals. Typhoidal toxins *cdtB*,

pltA and *pltB* were detected in *S*. Typhi, Rissen, Chester, and Telelkebir.

Conclusion:

This study revealed the West African dominant lineage 3.1.1 to be majority of *S*. Typhi

genotype harbouring ARGs. The increasing number of iNTS, including serovars harbouring

typhoidal toxins, as well as the dominance of multidrug resistant isolates emphasizes the need

for better diagnosis and surveillance of invasive *Salmonella*.

Author Summary

Whole genome sequencing of 63 invasive *Salmonella* from 5 tertiary hospitals in Nigeria revealed multiple serovars including a dominant antibiotic-resistance-gene harbouring *S.* Typhi 3.1.1 genotype comprising a *gyrA_S83Y* and IncY plasmid. We also report invasive non-typhoidal *Salmonella* harbouring typhoidal toxins.

 INTRODUCTION

Salmonella are a group of Gram negative, motile, facultative anaerobic rod-shaped bacteria

belonging to the Enterobacteriaceae family. This genus consists of two known species,

Salmonella enterica and *Salmonella bongori*. *S. enterica* are further distributed across six

subspecies, of which the *S. enterica* subsp. *enterica* are most reported in infections involving

homeotherm animals (1). Furthermore, *S. enterica* subsp. *enterica* consists of over 1500

serovars differentiated by distinct antigenic specificity (2). The human host adapted *S.*

enterica subsp. *enterica* serovars are usually associated with three marked clinical

syndromes. *Salmonella enterica* subsp. *enterica* serovar Typhi cause typhoid fever, and the

non-typhoidal Salmonella (NTS) cause bacteraemia and gastroenteritis in

immunocompromised (including persons with advanced HIV disease, cases of severe malaria

and malnutrition in children) and immunocompetent persons, respectively (3,4). S. Paratyphi

produce a syndrome similar to typhoid fever.

The public health impact of *Salmonella* infections is significant particularly in Africa and

Asia where they have a great influence on morbidity and mortality (5,6). For instance, an

estimated 17.8 million cases of typhoid fever occur each year in low and middle-income

countries (LMICs) (7). An earlier estimate suggests that the burden of typhoid fever is >100

per 100000 individuals per annum in sub-Saharan Africa with an associated 1% mortality

(8,9). Furthermore, an estimated 26% (33,490 lives lost) of the annual global typhoid-related

mortality is reported to occur in Africa (9). The disease burden of typhoid in Nigeria is

estimated at 364,791 typhoid cases resulting in 4,232 deaths (affecting 68% of individuals

under 15 years of age) as at 2016 (10), however population-based data are only just becoming

available (11). On the other hand, globally, NTS is estimated to cause approximately 94

million cases of gastroenteritis per annum worldwide with a resultant mortality of 155,000

(12). In immunocompromised cases of the disease (amongst HIV-positive adults), NTS is

reported to cause a 20% case fatality (212,000 deaths) in sub-Saharan Africa (SSA) annually,

while also being responsible for over 1 million cases of bloodstream infections in children in

SSA with a case fatality of 18.1% (197,000 child mortality) (4,13,14).

Although available reports suggest infection with *Salmonella enterica* to be the most

common cause of bloodstream infections in Africa (15), the incidence and microbiology of

typhoidal and invasive non-typhoidal Salmonella (iNTS) is still poorly understood. Many

regions on the continent have garnered little or no attention in the literature (7). Blood

culture-based surveillance represent standard methods for assessing the epidemiology and

aetiology of the invasive infections (16). However, limited surveillance of invasive

Salmonella on the Africa continent is majorly due to financial, logistical, and infrastructural

constraints for the institution of blood culture-based surveillance systems in the region

(7,8,16,17).

Such limitations not only obscure the true burden and prevalence of invasive *Salmonella*

infections in resource limited settings but also limit opportunity for genomic surveillance of

this pathogen. For instance, despite the huge burden of typhoid infections in Nigeria, there

are only 131 Salmonella genomes (all *S*. Typhi) from the country on Pathogenwatch

(https://pathogen.watch/, 15th November 2021) (18), a web-based platform for surveillance

of microbial genomes all of which were collected on or before 2013, and most from only two

centres. Lack of genomic surveillance information of invasive Salmonella in resource-limited

countries, including Nigeria, may deter interventions necessary to ameliorate this burden,

such as the typhoid conjugate vaccines (8,19,20). Hence, this report provides genomic

characterization of 2016-2020 invasive *Salmonella* retrieved from tertiary hospitals enrolled

into Nigeria's Antimicrobial Surveillance Network coordinated by the Nigeria Centre for

Disease Control (NCDC).

MATERIALS AND METHODS

Ethical considerations

Isolates were obtained as part of the surveillance efforts in line with Nigeria's national action plan. Ethical approval for using them in research was obtained from the University of Ibadan/University College Hospital ethics committee (UI/EC/15/093).

Isolate collection and Identification

Tertiary hospitals located in southwest Nigeria and enrolled into the Nigeria Antimicrobial Surveillance Network provided cryopreserved isolates from blood and cerebrospinal fluid to the AMR National reference laboratory. The isolates were from batched periods of 2016-2018 (retrospective isolates), 2019 and 2020. The national reference lab in partnership with the Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance (GHRU-GSAR) conducted the re-identification of the isolates using a VITEK 2 systems (version 2.0, Biomérieux).

DNA extraction and Library preparation

The isolates were processed for the extraction of genomic DNA using Wizard DNA extraction kit (Promega; Wisconsin, USA) following manufacturer's instructions. The extracted DNA was quantified on a Qubit fluorometer (Invitrogen; California, USA) using dsDNA Broad Range quantification assay. Double-stranded DNA libraries were prepared using the Covaris LC220 for fragmentation, and NEBNext Ultra II FS DNA library kit for Illumina with 384-unique indexes (New England Biolabs, Massachusetts, USA; Cat. No: E6617L). Libraries were sequenced on an Illumina HiSeq X10 (Illumina, CA, USA).

Genome Assembly

Generated sequence reads from Illumina runs were *de novo* assembled following GHRU

protocols (https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/assembly) using a Nextflow

workflow which inclusively comprises of adapter trimming (trimmomatic v0.38),

contamination detection (ConFindr v0.7.2), assembly (SPAdes v3.12.0), Quality Control

(multiqc v1.7, qualifyr v1.4.4) and Bactinspector (v 0.1.3).

Sequence typing of *Salmonella* genomes

Sequence reads were deposited in the *Salmonella* database on EnteroBase (Zhou et al., 2020).

Multi-locus sequence types (MLST) for the isolates were determined and core-genome

MLST calculated. Evolutionary relationship based on cgMLST of all *S*. Typhi of human

origin from Africa deposited in Enterobase were determined (Zhou et al., 2020). The

Salmonella genome assemblies were analysed using the *Salmonella* In-Silico Typing

Resource (SISTR) for the prediction of serovars and serogroups (https://github.com/phac-

nml/sistr_cmd). Serovars belonging to *S*. Typhi were loaded unto pathogen watch for the

prediction of their genotypes (Argimón et al., 2021).

Prediction of AMR, Plasmids, Virulence and Salmonella Pathogenicity islands

Prediction of AMR and virulence determinants, multi-locus sequence types (MLST) and

plasmid replicons were done following GHRU protocols

(https://gitlab.com/cgps/ghru/pipelines). Prediction of salmonella pathogenicity islands (SPIs)

in the genomes was done by mapping raw reads to SPIs database

(https://bitbucket.org/genomicepidemiology/spifinder_db)

Single Nucleotide Polymorphism (SNP) calling and phylogeny

The sequence reads of the Salmonella genomes from our study were mapped to NCBI

reference sequence, Salmonella enterica subsp. enterica serovar Typhi strain H12ESR00755-

001A (Assemby accession: GCF_001362195.2), to determine evolutionary relationship

amongst the strains following GHRU nextflow SNP phylogeny protocols

(https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny). SNP distances between the genome

pairs were calculated using snp-dists (https://github.com/tseemann/snp-dists) on the pseudo-

genome alignment.

Availability of sequence data

172 Raw sequence data generated from this study are deposited in the European Nucleotide

173 Archive under Bioproject PRJEB29739. Accession numbers for each genomes are available

174 as Supplementary information.

176 *RESULTS*

Invasive Salmonella from sentinel hospitals from Nigeria's AMR Surveillance Network

A total of 69 invasive and presumptive *Salmonella* spp. identified using VITEK at the

reference laboratory were retrieved from patients from five (n=5) sentinel hospitals.

However, whole-genome sequencing confirmed 61 of these to be *Salmonella enterica*, as

well as two *Salmonella enterica* isolates initially identified as *Escherichia coli* and

Acinetobacter baumanii using VITEK. (Five VITEK-identified '*Salmonella*' were *Klebsiella*

spp and one an *Enterobacter* spp. Strain). The sixty-three (63) WGS-confirmed invasive

Salmonella isolates were retrieved from blood (n=60) and cerebrospinal fluid (n=3). The

sending sentinel hospitals include: University of Ilorin Teaching Hospital (ILO, Ilorin, Kwara

State, n=25), University College Hospital, Ibadan (UCH, Ibadan, Oyo State, n=23), Obafemi

Awolowo University Teaching Hospital, Ile-Ife (OAU, Ile-Ife, Osun State, n=8), Lagos

University Teaching Hospital (LUT, Idi-Araba, Lagos State, n=4) and Babcock University

Teaching Hospital (BUT, Ilishan-Remo, Ogun State, n=3). The hospitals are all in the

southwestern part of Nigeria with ILO just north of the South-West geopolitical zone and all

the rest within it. All the *Salmonella* isolates from cerebrospinal fluid were obtained from

LUT.

Distribution of *Salmonella enterica* subsp. *enterica serovars* across sentinel hospitals

All the *Salmonella enterica* isolates belonged to the subspecies *enterica* but differed by

serotype with a total of 10 serovars detected. They include Typhi (n=46), Enteritidis (n=7),

Durham (n=2), Rissen (n=2), Adabraka (n=1), Chester (n=1), Dublin (n=1), Infantis (n=1),

Telelkebir (n=1), Typhimurium (n=1). Three *Salmonella enterica* isolates belonging to

serovars Adabraka (n=1) and Typhi (n=2) were retrieved from cerebrospinal fluid from LUT.

All other *Salmonella* serovars were retrieved by blood culture at the respective sentinel sites

(Supplemenary data 1). *Salmonella* Typhi and iNTS were recovered from all sentinel sites,

with iNTS being much less frequently recovered. Among the iNTS, S. *Enteritidis* was the

most ubiquitous, being recovered in three of the five sentinels. The other iNTS serovars

recovered more than once were *S*. Rissen =2 and *S*. Durham =2, both from UCH, which had

the broadest range of iNTS serovars (4).

Sequence types, genotypes, and Nucleotide polymorphisms.

Salmonella sequence-typing based on Achtman's MLST scheme (21) identified two *S*. Typhi

Sequence Types (STs) (ST1 =1 and ST2 = 45). There were nine different iNTS STs. These

included previously reported invasive STs: *S* Enteritidis ST11 (n=7) and *S* Typhimurium

ST313 (n=1), which are repeatedly reported from Africa. Other iNTS were *S*. Dublin (ST10),

S. Enteritidis (ST11), *S*. Typhimurium (ST313), *S*. Infantis (ST603), *S*. Durham (ST2010), *S*.

Chester (ST2063), *S*. Telelkebir (ST2222). Two novel STs belonging to *S*. Rissen and *S*.

Adabraka were curated and designated STs 8756 and 8757 respectively by EnteroBase.

To further place our *S*. Typhi genomes in a wider context, we performed MLST analysis

based on differences in core genomes of our strains and all *S*. Typhi from Human sources in

Africa deposited in EnteroBase (Fig 1). *S*. Typhi genomes from this study clustered with

others from West Africa, including Nigeria, Cameroon, Togo, Mauritania, Mali, Burkina

Faso, Guinea, Benin, and Ivory Coast, emphasizing further on their endemicity in the West

Africa region (Fig 1).

Further, based on *S*. Typhi genotyping scheme, we observed that *S*. Typhi ST1 belonged to

genotype 4.1 (UCH), whereas genotypes 2.3.1 (n=1, UCH) and 3.1.1 (n= 44) were *S*. Typhi

ST2 isolates. In addition, *S*. Typhi genomes from CSF (n=2) belonged to the 3.1.1 genotype.

Expectedly, *S*. Typhi genotypes 2.3.1 and 4.1 accounted for greatest pairwise SNP difference

among the *S*. Typhi genomes (between 397 to 549 single nucleotide substitutions), whereas

SNP differences ranged between 0 and 47 in the other *S*. Typhi genomes (genotype 3.1.1)

from the 5 sentinel hospitals. Among *S*. Enteritidis pairwise SNP difference ranged from 0 to

37 in the three sentinel labs (UCH, OAU, ILO) where they were isolated. *S*. Enteritidis

isolates from ILO (n=3) were near identical having pairwise SNP range from 0 to 1, whereas

it was between 0 and 32 in UCH.

Antimicrobial resistance determinants and plasmids replicons in TS and NTS

A combined total of 14 acquired antimicrobial resistance genes (ARGs) conferring resistance

to drugs within seven antibiotic classes were detected amongst the genomes (Fig 2,

Supplementary data).

Amongst the *S*. Typhi genomes, 76.08% (n=36/46) harboured at least one ARG specifying

reduced susceptibility to 5 antibiotic classes, with 89.13% harbouring a sulphonamide

resistance gene [*sul1* – 19.56% (n=9/46), *sul2* – 71.73% (n=33/46)] and 84.78% (n=39/46)

each harbouring a beta-lactam (bla$_{TEM-1}$), tetracyclines (*tetA* [n=33, 71.73%] and *tetB* [n=6,

13.04%]), and trimethoprim resistance determinant (*dfrA1* [n=1, 2.17%], *dfrA15* [n=8,

17.39%] and *dfrA14* [n=30, 65.21%]). In addition, quinolone resistance genes, *catA1*, were

also detected in the genomes (n=8, 17.39%). Chromosomal gene mutations occurring among

the sequenced *S*. Typhi isolates were those associated with the quinolone resistance

determining region *gyrA_S83Y* SNPs (n=37, 84.09%), which mediate reduced susceptibility

to fluoroquinolones. Furthermore, 97.82% (n=45) of the *S*. Typhi genomes had at least one

plasmid predicted to occur in each genome. Majority (71.73%, n=33) possessed an IncY

plasmid replicon, plasmid replicons IncFIA_HI1, IncHIA and IncHIB were respectively

detected in 19.56% (n=9) of *S*. Typhi genomes whereas one isolate harboured an IncQ

plasmid replicon.

For the iNTS, *S*. Enteritidis genomes possessed at least one ARG to six antibiotic classes. All

Isolates of this serotype harboured *aph(3'')-Ib*, bla$_{TEM-1}$, *catA1*, *dfrA7*, *sul1*, *sul2*, *tet(B)*

genes, and only differed in the absence/presence of *aph(6)-Id* (n=4, 57.14%). In tandem, *S*.

Typhimurium harbour ARGs [*aadA1*, *aph(3'')-Ib*, *aph(6)-Id*, bla$_{TEM-1}$, *catA1*, *dfrA1*, *sul1*,

sul2] specifying resistance to 5 antibiotic classes. The only occurring quinolone resistance

gene among isolates in this study, *qnrB19*, was detected in *S*. Telelkebir. No ARGs were

detected in *Salmonella* serovars Chester, Rissen, Durham, Infantis, Adabraka and Dublin.

Chromosomal gene mutations among iNTS were associated with *gyrA* and *parC* gene

regions. The quinolone resistance conferring *gyrA_D87Y* SNPs were detected only amongst

S. Enteritidis (ILO = 3 and UCH = 1), whereas quinolone resistance conferring *parC_T57S*

SNPs were detected in all iNTS except *S*. Enteritidis and *S*. Typhimurium. Plasmids were

predicted to occur only in *S*. Dublin [IncFII(S), IncX1 and IncX1_1], *S*. Enteritidis (IncI1 and

IncQ1), *S*. Typhimurium [IncFIB, IncFII(S) and IncQ1] among the iNTS.

Predominant IncY + gyrA_S83Y harbouring *S*. Typhi variants in Nigeria

We observe that all *S*. Typhi of the 3.1.1 lineage harbouring an IncY plasmid replicon

(71.73%, n=33/46) similarly possessed the *gyrA_S83Y* chromosomal gene mutation and

harboured a *tetA* gene. This phenomenon was observed to occur in all the sentinel hospitals in

this study. Additionally, pairwise SNP distance between the variants ranged from 0 to 18.

***Salmonella* virulence determinants and predicted pathogenicity islands**

The isolates possessed a plethora of virulence determinants (Supplementary data). Among the

S. Typhi genomes, a total of 98 virulence determinants were detected, and 97 (98.97%) of

these were conserved within members of this serovar (difference from the absence of *pipB2*

gene in an *S*. Typhi 3.1.1 from UCH). Expectedly, a wider variety of virulence determinants

were seen among iNTS, compared to *S*. Typhi. A total of 122 virulence genes were detected

in the iNTS genomes, and 86 (70.49%) of these were conserved in all iNTS genomes. For

instance, the iNTS possessed genes encoding (i) Adherence; such as AgF – thin aggregative

fimbrae or curli (*csgABCDEGF*), MisL – an autotransporter protein, Pef - plasmid-encoded

fimbrae (present only in *S*. Typhimurium) *ratB* (carried by iNTS strains harbouring CS54

islands), *shdA* (only found in *S*. Infantis), SinH (detected in all NTS except S. Enteritidis) and

Type 1 fimbrae (*fimCDFHI*) (ii) Stress adaptation; *sodCI* – superoxide dismutase (detected in

iNTS serovars except Durham, Chester and Rissen and Infantis and Telelkebir), *sopA* (not

detected in *S*. Infantis) (iii) Nutritional/metabolic factor (*mgtBC*, present in all strains) (iii)

Antimicrobial activity/competitive advantage; such as macrophage inducible genes (*mig-14*,

present in all strains) and (iv) Enterotoxin; T3SS effectors – *spvB* (In S. Typhimurium,

Enteritidis and Dublin), AvrA (In all iNTS except *S*. Dublin) and Typhoidal toxin - *cdtB*

(present in *S*. Durham, *S*. Telelkebir and *S*. Chester).

Since the *cdtB* are reported to be co-located with other cytolethal distending toxins (cdt),

pertussis-like toxins A (*pltA*) and B (*pltB*), on same pathogenicity islet (Simon et al., 2014),

we ran a blast search of our strains for the presence of *pltA* and *pltB*. The nucleotide

sequences were extracted from the virulence factor database (VFDB) and used as a local

database for a blast search against our iNTS genomes. Our results reveal high similarity

(100% coverage and $\geq$ 96.62% identity) with *cdtB*, *pltA* and *pltB* genes in the iNTS genomes

(*S*. Chester, *S*. Durham and *S*. Telelkebir).

Prediction of Salmonella pathogenicity islands (SPIs) gave 11 and 12 hits in *S*. Typhi and

iNTS genomes respectively. All *S*. Typhi were predicted to have 10 SPIs, i.e., SPI-1, SPI-2,

SPI-3, SPI-4, SPI-5, SPI-6, SPI-7, SPI-8, SPI-9, SPI-10 and SPI-12. However, SPI-4 was

predicted to occur only in *S*. Typhi lineages 2.3.1 and 4.1. In contrast to *S*. Typhi, only SPI-3

was predicted to occur in all the iNTS genomes. SPIs were shown to be associated with

members of certain serovars. For instance, SPI-2 and SPI-8 were detected only in *S*.

Typhimurium and *S*. Rissen, respectively. Other pathogenicity islands were detected in this

study (Fig 3, supplementary data), such as SPI-4 (*S*. Adabraka, Chester, Typhimurium), SPI-6

(all NTS except *S*. Durham, Rissen and Telelkebir), SPI-12 (all NTS except S. Chester,

Durham, Rissen and Telelkebir) and CS54_island was detected in *S*. Dublin, *S*.

Typhimurium, *S*. Infantis and *S*. Enteritidis (n=6/7, 85.71%).

Microreact main data:

https://microreact.org/project/3tgJwQ1mPBkep3sv9QzRv6-

ghruprojectinvasivesalmonella22-11-21

Microreact SPIs:

https://microreact.org/project/9M6qNGcvHNqwbjykmX9MaC-invasivesalmonellaspis

DISCUSSION

In this report we present outcome of genomic characterization of invasive *Salmonella*

infections from AMR surveillance in sentinel hospitals in Nigeria. The genomic

characterization of invasive Salmonella isolates in this study was possible because these

hospitals perform blood culture and enrolled in Nigeria's new antimicrobial resistance

surveillance system, which offers genomic services at the National Reference Laboratory

level (22). Nonetheless, blood culture is available at very few institutions in Nigeria, a

limitation still prevalent in many African settings that impacts the genomic surveillance of

invasive Salmonella. (8,16,23).

Using to high-throughput WGS and bioinformatic analytics, we were able to determine

prevalent multiple serotypes and dominant genotypes of invasive *Salmonella* infections. Most

of the isolates were *Salmonella* Typhi, which have been more frequently recovered in Nigeria

(24,25), even though iNTS may predominate at other African settings (3,26). While our data

are few, the predominance of Typhi at all sites points to a significant burden of severe disease

that could be averted were Typhoid Conjugate Vaccines available in Nigeria. Out of a total

of 10 *S*. Typhi genotypes recorded in Nigeria from Pathogenwatch, three were identified in

this study. The prevalence of *S*. Typhi genotype 3.1.1 in our report was similarly observed in

the Nigeria cluster on Pathogenwatch (n=87/131, 66.41%). As in our study, this cluster

possessed similar prevalence of genetic determinants of beta-lactam (bla_{TEM-1} – 83.90%)

resistance, indicating that these determinants are well-conserved in the genotype. However,

prevalence of other AMR genetic determinants from this lineage such as *catA1* (86.20%),

sul1 (87.35%), *sul2* (3.44%), *dfrA14* (4.39%), *dfrA15* (87.35%), *tetA* (78.16%), *tetB* (78.16)

were not similar from what is reported from this study (*catA1* –18.18%, *sul1* – 18.18%, *sul2* –

72.72%, *dfrA14* – 68.18%, *dfrA15* – 18.18%, *tetA* – 75%, *tetB* – 11.36).

This multidrug-resistance gene-encoding *S*. Typhi 3.1.1 is shown to be one of the broadest

lineages in sub-Saharan Africa and endemic in the West Africa region (Wong et al., 2016;

Park et al., 2018; Ingle et al., 2019). Additionally, we observed *S*. Typhi genotype 3.1.1 clone

variants harbouring IncY + *gyrA_S83Y* + *tetA* genes. The Pathogenwatch database contains

two strains isolated in Abuja, north-central part of the country in 2013 with similar clonal

characteristics. Our data suggest that the resistant sublineage is predominant in our setting

and should be sought elsewhere in Nigeria and the region.

S. Enteritidis were the most frequently recovered NTS in our study and were recovered at

three sentinel hospitals. This outcome contrasts with earlier reports of *S*. Typhimurium ST313

in Eastern Africa, but also present across the continent, including Nigeria (15,27,28), but is

concordant with more recent higher *S*. Enteritidis reports from invasive infections in The

Gambia (29). We observed that *S*. Enteritidis retrieved from different patients in ILO (in

2019) had highly similar genetic features (antimicrobial resistance determinants, virulence,

plasmids replicons) including pairwise SNP between 0 and 1. The isolates were recovered on

the 27th of June, 26th of August and 28th of August 2019 and their genetic, geographic and

temporal connectedness may be indicative of a previously unrecognized outbreak. Both *S*.

Typhimurium ST313 and *S*. Enteritidis ST11 are dominant, human-adapted clones in sub-

Saharan Africa (30) that are a major cause of invasive disease, with a corresponding high

case-fatality rate (14). These serovars are justifiably vaccine development priorities.

Invasive NTS vaccines in the pipeline will not cover other NTS serovars and we identified

several in this study, harbouring an assortment of virulence, plasmids and antimicrobial

resistance determinants. This points to the need for widespread and robust access to invasive

Salmonella diagnostics in Nigeria. The single occurrence of an acquired quinolone resistance

gene, qnrB19 in this study was detected in *S*.Telelkebir. To the best our knowledge, this

serovar has been reported just once on the African continent, in Mali (ENA accession number

SRR8987873). However, it is more commonly reported in parts of Europe, China and USA

(31). The expansion of atypical *Salmonella* serovars in invasive infections is associated with

a high health burden (19,29).

We observed that NTS (*S*. Telelkebir, *S*. Durham and *S*. Chester) harboured the cytolethal

distending toxin islet genes (*cdtB*, *pltA*, *pltB*) also known as typhoid toxin. These toxins were

originally thought to be restricted to serovars Typhi and Paratyphi A (32). However, these

have now been reported in other NTS serovars including Bredeney, Javiana, Montevideo,

Schwarzengrund, and more recently in Telelkebir (33–35). The cytolethal distending toxin

islet cause DNA damage and cell cycle arrest in impaired cells (36). More implicatively,

these genes encoded by NTS serovars have been reported to play vital roles in disease

pathogenesis (34,35). Thus, this study emphasizes on an expanding number of serovars

causing invasive infections in the country, and the public health implications therein.

CONCLUSION

The outcome of our study emphasizes the need for expanded genomic surveillance of

invasive *Salmonella* infections in Nigeria as a valuable tool to monitor antibiotic resistance

spread and genetic characterization of circulating lineages in Nigeria. Close monitoring of the

antibiotic resistance genes harbouring *S*. Typhi 3.1.1 IncY + *gyrA_S83Y* variants and other

serovars is vital, and this may inform strategies for empirical treatment and control of spread

of antibiotic resistant lineages. Our data demonstrate that introducing typhoid conjugate

vaccines, recommended by the World Health Organization for countries like Nigeria that

have a high typhoid disease burden, will have a significant impact on health (37). In addition,

development of vaccines which target NTS would be useful in reducing the overall burden of

NTS on the continent and rigorous surveillance is essential for determining which serovars

most require coverage. Even broader protective effects may be achieved by improvements in

water, sanitation and hygiene that could interrupt transmission of the causes of typhoid and

other invasive salmonellosis.

ACKNOWLEDGEMENT

This work was supported by Official Development Assistance (ODA) funding from the

National Institute of Health Research [grant number 16_136_111] and the Wellcome Trust

grant number 206194. INO was an African Research Leader supported by the UK Medical

Research Council (MRC) and the UK Department for International Development (DFID)

under the MRC/DFID Concordat agreement that is also part of the EDCTP2 program

supported by the European Union. The funders had no role in the content, crafting or

submission of this paper.

We thank Chinenye Ekemezie and Ifeoluwa Akintayo for excellent technical contributions

and Jola-Ade J. Ajiboye for logistic assistance. We are grateful to the administration and

staff of the five sentinels for supporting them in surveillance.

REFERENCES

1.   Giner-Lamia J, Vinuesa P, Betancor L, Silva C, Bisio J, Soleto L, et al. Genome

analysis of Salmonella enterica subsp. diarizonae isolates from invasive human

infections reveals enrichment of virulence-related functions in lineage ST1256. BMC

Genomics [Internet]. 2019 Jan 31 [cited 2021 Nov 9];20(1):1–14. Available from:

https://link.springer.com/articles/10.1186/s12864-018-5352-z

2.   Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, De Pinna E, Nair

S, et al. Supplement 2008–2010 (no. 48) to the White–Kauffmann–Le Minor scheme.

Res Microbiol. 2014 Sep 1;165(7):526–30.

3.   Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-

typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.

Lancet. 2012 Jun 30;379(9835):2489–99.

4.   Keestra-Gounder AM, Tsolis RM, Bäumler AJ. Now you see me, now you don't: the

interaction of Salmonella with innate immune receptors. Nat Rev Microbiol 2015 134

[Internet]. 2015 Mar 9 [cited 2021 Nov 9];13(4):206–16. Available from:

https://www.nature.com/articles/nrmicro3428

5.   Smith SI, Seriki & A, Ajayi & A. Typhoidal and non-typhoidal Salmonella infections

in Africa. Eur J Clin Microbiol Infect Dis.

6.   Phu Huong Lan N, Le Thi Phuong T, Nguyen Huu H, Thuy L, Mather AE, Park SE, et

al. Invasive Non-typhoidal Salmonella Infections in Asia: Clinical Observations,

Disease Outcome and Dominant Serovars from an Infectious Disease Hospital in

Vietnam. PLoS Negl Trop Dis [Internet]. 2016 Aug 11 [cited 2022 Jan

4];10(8):e0004857. Available from:

https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004857

7.   Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, et al. The

burden of typhoid fever in low- and middle-income countries: A meta-regression

approach. PLoS Negl Trop Dis [Internet]. 2017 Feb 27 [cited 2021 Nov

9];11(2):e0005376. Available from:

https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005376

8.   Crump JA, Heyderman RS. A Perspective on Invasive Salmonella Disease in Africa.

Clin Infect Dis [Internet]. 2015 Nov 1 [cited 2021 Nov 2];61(suppl_4):S235–40.

Available from: https://academic.oup.com/cid/article/61/suppl_4/S235/458434

9.   Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale V V., Ramani E, et al. Burden

of typhoid fever in low-income and middle-income countries: a systematic, literature-

based update with risk-factor adjustment. Lancet Glob Heal. 2014 Oct 1;2(10):e570–

80.

10. TyVAC. Potential of typhoid conjugate vaccines in Nigeria [Internet]. 2017. 2017 Nov

[cited 2021 Nov 13]. Available from: https://www.coalitionagainsttyphoid.org/wp-

content/uploads/2017/11/TCV-country-specific-factsheet-Nigeria_final.pdf

11. Park SE, Toy T, Cruz Espinoza LM, Panzner U, Mogeni OD, Im J, et al. The Severe

Typhoid Fever in Africa Program: Study Design and Methodology to Assess Disease

Severity, Host Immunity, and Carriage Associated with Invasive Salmonellosis. Clin

Infect Dis [Internet]. 2019 Oct 30 [cited 2021 Nov 2];69(Supplement_6):S422–34.

Available from: https://academic.oup.com/cid/article/69/Supplement_6/S422/5609450

12. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, et al. The global

burden of nontyphoidal salmonella gastroenteritis. Clin Infect Dis [Internet]. 2010 Mar

15 [cited 2021 Nov 10];50(6):882–9. Available from:

https://academic.oup.com/cid/article/50/6/882/419872

13. Gordon MA. Salmonella infections in immunocompromised adults. J Infect. 2008 Jun

1;56(6):413–22.

14. Reddy EA, Shaw A V., Crump JA. Community-acquired bloodstream infections in

Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Jun

1;10(6):417–32.

15. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A Systematic Review

and Meta-analysis of the Prevalence of Community-Onset Bloodstream Infections

among Hospitalized Patients in Africa and Asia. 2019 [cited 2021 Nov 9]; Available

from: https://doi.org/10.1128/AAC.01974-19.

16.   Ombelet S, Barbé B, Affolabi D, Ronat J-B, Lompo P, Lunguya O, et al. Best

Practices of Blood Cultures in Low- and Middle-Income Countries. Front Med

[Internet]. 2019 Jun 18 [cited 2021 Nov 11];6. Available from:

/pmc/articles/PMC6591475/

17.   Balasubramanian R, Im J, Lee JS, Jeon HJ, Mogeni OD, Kim JH, et al. The global

burden and epidemiology of invasive non-typhoidal Salmonella infections.

https://doi.org/101080/2164551520181504717 [Internet]. 2018 Jun 3 [cited 2021 Nov

26];15(6):1421–6. Available from:

https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1504717

18.   Argimón S, Yeats CA, Goater RJ, Abudahab K, Taylor B, Underwood A, et al. A

global resource for genomic predictions of antimicrobial resistance and surveillance of

Salmonella Typhi at pathogenwatch. Nat Commun 2021 121 [Internet]. 2021 May 17

[cited 2021 Nov 14];12(1):1–12. Available from:

https://www.nature.com/articles/s41467-021-23091-2

19.   Balasubramanian R, Im J, Lee JS, Jeon HJ, Mogeni OD, Kim JH, et al. The global

burden and epidemiology of invasive non-typhoidal Salmonella infections.

https://doi.org/101080/2164551520181504717 [Internet]. 2018 Jun 3 [cited 2021 Nov

10];15(6):1421–6. Available from:

https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1504717

20.   Carey ME, Steele AD. The Severe Typhoid Fever in Africa Program Highlights the

Need for Broad Deployment of Typhoid Conjugate Vaccines. Clin Infect Dis

[Internet]. 2019 Oct 30 [cited 2021 Nov 26];69(Supplement_6):S413–6. Available

from: https://academic.oup.com/cid/article/69/Supplement_6/S413/5609446

21.   Achtman M, Wain J, Weill FX, Nair S, Zhou Z, Sangal V, et al. Multilocus Sequence

Typing as a Replacement for Serotyping in Salmonella enterica. PLOS Pathog

[Internet]. 2012 [cited 2022 Jan 20];8(6):e1002776. Available from:

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002776

22.   Afolayan AO, Oaikhena AO, Aboderin AO, Olabisi OF, Amupitan AA, Abiri O V, et

al. Clones and Clusters of Antimicrobial-Resistant Klebsiella From Southwestern

Nigeria. Clin Infect Dis. 2021;73(Supplement_4):S308–15.

23.   Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA. Laboratory medicine in

Africa: A barrier to effective health care. Clin Infect Dis [Internet]. 2006 Feb 1 [cited

2021 Nov 25];42(3):377–82. Available from:

https://academic.oup.com/cid/article/42/3/377/378561

24.   Obaro SK, Hassan-Hanga F, Olateju EK, Umoru D, Lawson L, Olanipekun G, et al.

Salmonella Bacteremia Among Children in Central and Northwest Nigeria, 2008–

2015. Clin Infect Dis [Internet]. 2015 Nov 1 [cited 2022 Jan 4];61(suppl_4):S325–31.

Available from: https://academic.oup.com/cid/article/61/suppl_4/S325/459582

25.   Popoola O, Kehinde A, Ogunleye V, Adewusi OJ, Toy T, Mogeni OD, et al.

Bacteremia Among Febrile Patients Attending Selected Healthcare Facilities in Ibadan,

Nigeria. Clin Infect Dis [Internet]. 2019 Oct 30 [cited 2022 Jan

4];69(Supplement_6):S466–73. Available from:

https://academic.oup.com/cid/article/69/Supplement_6/S466/5609444

26.   Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of

invasive nontyphoidal Salmonella disease, 2010(1). Emerg Infect Dis [Internet]. 2015

Jun 1 [cited 2022 Jan 4];21(6):941–9. Available from:

https://pubmed.ncbi.nlm.nih.gov/25860298/

27.   Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, et al.

Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in

sub-Saharan Africa have a distinct genotype. Genome Res [Internet]. 2009 Dec 1

[cited 2021 Nov 25];19(12):2279–87. Available from:

https://genome.cshlp.org/content/19/12/2279.full

28. Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN, et

al. Intracontinental spread of human invasive Salmonella Typhimurium pathovariants

in sub-Saharan Africa. Nat Genet 2012 4411 [Internet]. 2012 Sep 30 [cited 2021 Nov

25];44(11):1215–21. Available from: https://www.nature.com/articles/ng.2423

29. Kanteh A, Sesay AK, Alikhan N-F, Ikumapayi UN, Salaudeen R, Manneh J, et al.

Invasive atypical non-typhoidal Salmonella serovars in The Gambia. Microb

Genomics [Internet]. 2021 Nov 23 [cited 2021 Nov 25];7(11):000677. Available from:

https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000677

30. Park SE, Pham DT, Pak GD, Panzner U, Espinoza LMC, Kalckreuth V von, et al. The

genomic epidemiology of multi-drug resistant invasive non-typhoidal Salmonella in

selected sub-Saharan African countries. BMJ Glob Heal [Internet]. 2021 Aug 1 [cited

2021 Nov 2];6(8):e005659. Available from: https://gh.bmj.com/content/6/8/e005659

31. Qiu YF, Nambiar RB, Xu X Bin, Weng ST, Pan H, Zheng KC, et al. Global Genomic

Characterization of Salmonella enterica Serovar Telelkebir. Front Microbiol. 2021 Jul

29;12:2007.

32. Tamamura Y, Tanaka K, Uchida I. Characterization of pertussis-like toxin from

Salmonella spp. that catalyzes ADP-ribosylation of G proteins. Sci Reports 2017 71

[Internet]. 2017 Jun 1 [cited 2021 Nov 24];7(1):1–13. Available from:

https://www.nature.com/articles/s41598-017-02517-2

33. den Bakker HC, Moreno Switt AI, Govoni G, Cummings CA, Ranieri ML, Degoricija

L, et al. Genome sequencing reveals diversification of virulence factor content and

possible host adaptation in distinct subpopulations of Salmonella enterica. BMC

Genomics [Internet]. 2011 Dec 22 [cited 2021 Nov 25];12(1):1–11. Available from:

https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-12-425

34.   Mezal EH, Bae D, Khan AA. Detection and functionality of the CdtB, PltA, and PltB

from Salmonella enterica serovar Javiana. Pathog Dis [Internet]. 2014 Nov 1 [cited

2021 Nov 25];72(2):95–103. Available from:

https://academic.oup.com/femspd/article/72/2/95/629542

35.   Rodriguez-Rivera LD, Bowen BM, Den Bakker HC, Duhamel GE, Wiedmann M.

Characterization of the cytolethal distending toxin (typhoid toxin) in non-typhoidal

Salmonella serovars. Gut Pathog [Internet]. 2015 Jul 24 [cited 2021 Nov 24];7(1):1–7.

Available from: https://gutpathogens.biomedcentral.com/articles/10.1186/s13099-015-

0065-1

36.   Chang SJ, Jin SC, Jiao X, Galan JE. Unique features in the intracellular transport of

typhoid toxin revealed by a genome-wide screen. PLOS Pathog [Internet]. 2019 [cited

2021 Nov 21];15(4):e1007704. Available from:

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1007704

37.   WHO. WHO recommends use of first typhoid conjugate vaccine [Internet]. 2018

[cited 2021 Nov 26]. Available from: https://www.who.int/news/item/03-04-2018-

who-recommends-use-of-first-typhoid-conjugate-vaccine

Figure Legends

Fig 1: Grape tree showing core genome MLST of *S*. Typhi from human sources in Africa,

deposited in the EnteroBase database. Red leaf labels are genomes from this study

Fig 2: A SNP-phylogeny based tree and heatmap showing the genomic profile of *Salmonella*

genomes retrieved from 5 sentinel laboratories in Nigeria

Fig 3: Frequency of occurrence of *Salmonella* pathogenicity island in TS (Typhoidal

Salmonella) and NTS (Non-typhoidal Salmonella).

Fig 1: Grape tree showing core genome MLST of *S*. Typhi from human sources in Africa, deposited in the EnteroBase database. Red leaf labels are genomes from this study

Fig 2: A SNP-phylogeny based tree and heatmap showing the genomic profile of *Salmonella* genomes retrieved from 5 sentinel laboratories in Nigeria.

Fig 3: Frequency of occurrence of *Salmonella* pathogenicity island in TS (Typhoidal Salmonella) and NTS (Non-typhoidal Salmonella).